An open‐label phase II study: The efficiency and safety of anlotinib + eribulin in patients with HER2 ‐negative metastatic breast cancer
International Journal of Cancer · 2026
DOI: 10.1002/ijc.70079 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift International Journal of Cancer, 2026. Verfasst von Xinyu Wu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. Hauptthemen laut MEDLINE: Ketones, Furans, Breast Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: Beijing Xisike Clinical Oncology Research Foundation, National Natural Science Foundation of China.
Abstract (Originalsprache)
This research (NCT04624711) evaluated the efficacy and safety of eribulin plus anlotinib in patients with HER2‐negative metastatic breast cancer (mBC) and explored the potential synergistic benefits of this combination. A total of 70 women with HER2‐negative breast cancer who had previously undergone anthracycline‐ or taxane‐based therapies were enrolled. Hormone receptor‐positive patients had also received CDK4/6 (Cyclin‐dependent kinase 4/6) inhibitor‐based endocrine therapy. All patients were treated with eribulin mesylate (1.4 mg/m 2 , administered intravenously on days 1 and 8) and anlotinib (12 mg orally, once daily on days 1–14) in 21‐day cycles. The median progression‐free survival (mPFS) was 7.00 months, with an objective response rate (ORR) of 50.00% and a disease control rate (DCR) of 94.29%. Patients with fewer than two visceral metastases exhibited a significantly longer median PFS than those with multiple visceral metastases (8.93 months vs. 6.90 months, p = 0.0337). The most common treatment‐related adverse events (TRAEs) were neutropenia (67.14%) and leukopenia (68.57%), with 41.43% and 27.14% of patients experiencing grade 3/4 hematologic toxicities, respectively. These findings suggest that the combination of eribulin and anlotinib demonstrated encouraging efficacy and a manageable safety profile, offering a potential therapeutic option for patients with HER2‐negative mBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
- Department of Oncology, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, China.
- Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
ORCID-Profile: Xinyu Wu, Yongmei Yin
Förderung
- Beijing Xisike Clinical Oncology Research Foundation
- National Natural Science Foundation of China
Zitieren
APA
Wu, X., Qu, F., Hua, Y., Lu, R., Jin, N., Liang, Y., Sun, C., Yang, F., Li, W., Huang, X., & Yin, Y. (2026). An open‐label phase II study: The efficiency and safety of anlotinib + eribulin in patients with HER2 ‐negative metastatic breast cancer. International Journal of Cancer. https://doi.org/10.1002/ijc.70079
Vancouver
Wu X, Qu F, Hua Y, Lu R, Jin N, Liang Y, et al. An open‐label phase II study: The efficiency and safety of anlotinib + eribulin in patients with HER2 ‐negative metastatic breast cancer. International Journal of Cancer. 2026. doi:10.1002/ijc.70079
BibTeX
@article{Wu2026,
author = {Wu, Xinyu and Qu, Fei and Hua, Yijia and Lu, Rongrong and Jin, Nan and Liang, Yan and Sun, Chunxiao and Yang, Fan and Li, Wei and Huang, Xiang and Yin, Yongmei},
title = {An open‐label phase II study: The efficiency and safety of anlotinib + eribulin in patients with HER2 ‐negative metastatic breast cancer},
journal = {International Journal of Cancer},
year = {2026},
doi = {10.1002/ijc.70079}
}
EUVIMED